Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Hpv: early-phase trial registry

15 of 25 indexed Hpv trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 15 currently recruiting · #652 of 28,707 conditions by registered trial count

Hpv: 25 US clinical trials tracked, 15 recruiting.

Hpv is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition hpv

OPEN 15 | RECR 60% | LATE 2 | EARLY 7 | RANK #652 | SPON 3

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Hpv (this)60%Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%
Open-enrollment share among volume-matched conditions near Hpv

Hpv lists 15 open slots (60% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hpv on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hpv is recruiting above its size-band peers.

    15 of 25 indexed trials (60%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hpv trials is spread across many organizations.

    National Cancer Institute (NCI) accounts for 3 of 25 trials (12%). 18 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hpv enrolment sits around 180 participants.

    Median target enrolment is 180 among the 25 trials that report a genuine target (sentinel values excluded). 7 of those (28%) plan for fewer than 100 participants.

  4. Hpv research is mostly interventional.

    21 interventional and 4 observational studies make up this index (84% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 42

Open and recent trials

25 total, page 1 of 1

RECRUITING NA 16,000 participants

Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination

University of Rochester

NCT06380114

RECRUITING NA 3,100 participants

The HPV 9-10 Trial: Early Initiation of HPV Vaccination

University of Colorado, Denver

NCT04722822

RECRUITING NA 1,000 participants

HPV Self-Collection Program

University of Utah

NCT06674681

RECRUITING NA 920 participants

Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening

M.D. Anderson Cancer Center

NCT06109870

RECRUITING 600 participants

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01011712

RECRUITING NA 450 participants

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

Qurasense

NCT07281599

RECRUITING NA 180 participants

Playing Game to Learn About Children's Vaccine Project

Michigan State University

NCT05984849

RECRUITING Phase 2 121 participants

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Memorial Sloan Kettering Cancer Center

NCT05491512

RECRUITING NA 120 participants

PopSci CHW4CervixHealth

Thomas Jefferson University

NCT07336134

RECRUITING Phase 4 100 participants

HPV Vaccine Reduced Dose

Emory University

NCT06799494

RECRUITING Phase 1 98 participants

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

University of Chicago

NCT05108870

RECRUITING Phase 2 38 participants

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

University of Chicago

NCT07065630

RECRUITING Phase 2 30 participants

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Memorial Sloan Kettering Cancer Center

NCT05307939

RECRUITING NA 30 participants

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

Georgetown University

NCT06902623

RECRUITING Phase 2 20 participants

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

M.D. Anderson Cancer Center

NCT05363709

ACTIVE NOT RECRUITING NA 21,110 participants

Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness

University of Florida

NCT05006833

ACTIVE NOT RECRUITING NA 870 participants

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

Teal Health

NCT06120205

ACTIVE NOT RECRUITING NA 200 participants

Advancing Cervical Cancer Screening Through the Emergency Department - IIS

University of Rochester

NCT06796738

ACTIVE NOT RECRUITING 150 participants

Post-treatment Surveillance in HPV+ Oropharyngeal SCC

Dana-Farber Cancer Institute

NCT04965792

ACTIVE NOT RECRUITING Phase 1 55 participants

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

National Cancer Institute (NCI)

NCT04708470

ACTIVE NOT RECRUITING Phase 4 17 participants

Assessing Durable Antibody Response to HPV Vaccination

Emory University

NCT05031078

COMPLETED 7,500 participants

Low-Cost Molecular Cervical Cancer Screening Study

National Cancer Institute (NCI)

NCT01231945

COMPLETED Phase 2 614 participants

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

Syracuse University

NCT00680147

COMPLETED 300 participants

Pilots of Self-Collection for HPV DNA Detection

National Cancer Institute (NCI)

NCT00342511

COMPLETED NA 170 participants

Pilot HPV Vaccination in Chinese American Community

Temple University

NCT04505930

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 4 2

Named interventions

Most-linked intervention names on Hpv records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Carboplatin Drug
3 trials
Gardasil-9 Biological
2 trials
Radiation Radiation
2 trials
Paclitaxel Drug
2 trials
General Vaccination Education Behavioral
1 trials
Interventional HPV vaccination video modules Behavioral
1 trials
brief informational intervention to promote HPV vaccine acceptance Behavioral
1 trials
Lidocaine injections Drug
1 trials

US sites by state

Facility locations filed on Hpv trials. A trial with sites in several states counts in each.

New York 6 trials
Maryland 4 trials
Texas 3 trials
Utah 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New Jersey 2 trials
Massachusetts 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hpv page

25 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hpv condition card totals 25 registered trials; most-linked intervention Carboplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.